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Background. Accurate blood pressure (BP) readings and correctly interpreting the obtained
values are of great importance. However, there is considerable variation in the different BP
measuring methods suggested in guidelines and used in hypertension trials.
Objective. To compare the different methods used to measure BP; measuring once, the
method used for a large study such as the UKPDS, and the methods recommended by various
BP guidelines.
Methods. In 223 patients with type 2 diabetes from five family practices BP was measured
according to a protocol to obtain the following data: A = first reading, B = mean of two initial
readings, C = at least four readings and the mean of the last three readings with less than 15%
coefficient of variation difference, D = mean of the first two consecutive readings with a
maximum of 5 mm Hg difference. Mean outcomes measure is the mean difference between
different BP measuring methods in mm Hg.
Results. Significant differences in systolic/diastolic BP were found between A and B [mean
difference (MD) systolic BP 1.6 mm Hg, P<0.001], B and C (MD 5.7/2.8 mm Hg, P<0.001), B and
D (MD 6.2/2.8 mm Hg, P<0.001), A and C (MD 7.3/3.3 mm Hg), and A and D (MD 7.9/3.0 mm Hg,
P<0.001).
Conclusion. Different methods to assess BP during one visit in the same patient lead to
significantly different BP readings and can lead to overestimation of the mean BP. These
differences are clinically relevant and show a gap between different methods in trials,
guidelines and daily practice.
Keywords. Blood pressure determination, clinical trials, human, hypertension, practice
guidelines.
Introduction
In hypertension, accurate blood pressure (BP) readings
and the correct interpretation of the obtained values
are of great importance to epidemiology as well as to
diagnosis, treatment and research.
1,2 Although a large
number of guidelines and recommendations describing
how blood pressure BP measured are available,
research shows that health care providers frequently
do not comply with these guidelines.
3–5 This leads to
possible mistakes in the diagnosis and treatment of
hypertension. Additionally, the guidelines are not
always consistent with each other. For example, the
European Society of Hypertension recommends calcu-
lating the mean of at least two BP readings on each
visit.
2 This method corresponds to the measuring
methods described in the seventh report of the Joint
National Committee on Prevention, Detection, Evalu-
ation, and Treatment of high blood pressure (the JNC7
report), the British Hypertension Society, the Dutch
College of General Practitioners and Perloff et al.
6–9
However, the Dutch Institute of Healthcare (CBO)
recommends taking as many readings as are necessary
to obtain two readings that are no >5 mm Hg apart
(systolic or diastolic).
10 The mean of these two readings
is then considered to be an accurate representation of
the patient’s BP. Furthermore (and potentially more
disturbing when it comes to interpreting data) studies
on antihypertensive medication or cardiovascular risk
prediction use different methods to measure BP, and
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20some studies do not report which method was used.
Table 1 shows that various protocols are used in these
trials to measure BP and that these protocols do not
always agree with the guidelines. The number of
measurements varies from one to six, the resting period
from 0 to 5 minutes, and the time interval between two
measurements from 0 to 30 seconds. The BP cut off
points in the guidelines, which are to be striven for in
patients with hypertension, are usually based on these
large clinical or epidemiological trials. For example,
based on the United Kingdom Prospective Diabetes
Study (UKPDS), until 2003, Dutch general practition-
ers aimed for a BP below 150/85 mm Hg in patients with
diabetes mellitus type 2 (according to more recent
guidelines, the target BP in these patients is 140/90 mm
Hg).
8,11–13 However, as we mentioned above, the
guidelines used by the Dutch general practitioners
describe a different method for measuring BP (mean of
the first two readings) than was used in the UKPDS
(4 readings, mean of the last three measurements).
The aim of our study is to compare the differences in
BP readings resulting from applying the different
methods in a single patient, during a single visit: the
method used most widely in daily practice (measuring
once), the methods recommended in various guidelines,
and the method used in the UKPDS.
Methods
Setting
In January 2003, all patients with diabetes mellitus type
2 registered in the group practice of five general
practitioners were invited by letter to come in for their
annual diabetes check-up. The annual check-up
includes BP measurement. Two trained physicians
were randomly assigned patients, and they followed a
standard protocol when taking the BP readings. All the
patients gave written informed consent.
Equipment
A calibrated OMRON M5-I (HEM-757) automatic
blood-pressure device was used. This device was vali-
datedaccordingtodifferentinternationalprotocols.
14–16
BP measurements
Before taking the blood pressure, the circumference of
the upper arm was measured. When the circumference
TABLE 1 Blood pressure measuring protocols as described in some large trials on antihypertensive therapy
Trial References Device Mercury/aneroid/
automatic
Method
(auscultatory/
oscillometric)
Measurement protocol Blood pressure
value used
for the study
UKPDS 22,23 Copal UA.251 or Automatic Auscultatory Sitting, at least
5 minutes rest,
minimal 4 readings
Mean of 2nd, 3rd, and
4th reading with a
coefficient of variation
below 15%
Takeda UA.751 Automatic Auscultatory
Hawksley RZS Mercury Auscultatory
ALLHAT 24,25 Standardised techniques,
no further description
Not described Not described 2 readings
(30 seconds interval)
Mean of both readings
LIFE 26–28 Standardised techniques,
no further description
Not described Not described Sitting, after
5 minutes rest
Not described
HOT 29 Visomat OZ D2 Automatic Oscillometric Sitting, after 5 minutes
rest, 3 readings
Mean of all three
readings
RENAAL 30, 31 Not described Not described Not described Sitting, after 5 minutes
rest, 3 readings
Mean of all three
readings
ANBP2 32, 33 Not described Mercury Auscultatory Sitting, 2 readings Not described
HOPE 34, 35 Not described Not described Not described Not described Not described
IRMA2 36 Sphygmomanometer Not described Not described Sitting, after 10 minutes
rest, 2 readings
(2 minutes interval)
Mean of both readings
Syst-Eur 37–39 Not described Not described Not described Sitting, at randomisation:
6 readings;
follow-up measurements:
not described
Mean of six readings
(at randomisation)
SHEP 40 Hawksley RZS Mercury Auscultatory sitting, 2 readings Mean of both readings
PROGRESS 41 Not described Mercury Auscultatory 2 readings Not described
Pitfalls in blood pressure measurement 21was 22–32 cm, the standard cuff (12 · 21.5 cm) was used.
For circumferences between 32 and 42 cm, the large
cuff (15 · 29.5 cm) was used. The measurement was
done with the patient in a sitting position, after he or
she had been sitting for a minimum of 5 minutes, in such
a way that the cuff was at heart level and the volar side
of the lower arm rested on the desk. The cuff was
applied to the bare arm 1–2 cm above the elbow fold.
Any tight clothing was removed from the upper arm.
The patient was asked to sit still, not to move the arm,
and not to speak during measurement. The time
interval between successive measurements was at
least 15 seconds.
10 Initially, BP was measured twice
in each arm, with the choice of arm at the discretion of
the patient. The first reading was recorded as such. The
mean of the two readings for the left arm was compared
with the mean for the right arm. When there was a
difference of >10 mm Hg between the systolic and/or
diastolic BP readings, the measurements were contin-
ued on the arm with the higher BP, which is according
to the Dutch guidelines.
8,10 When the difference
was less, an arbitrary arm was taken for the next
measurements. This arbitrary arm or the arm with the
higher BP was used to obtain the mean of two BP
readings. Again, two more readings were done, bringing
the total number of readings for one individual in one
arm to four. When a coefficient of variation above 15%
(SD*100%/mean) in the last three consecutive mea-
surements was found, additional readings were taken
until the last three were below 15% (to comply with the
UKPDS protocol). Furthermore, readings were taken
until two readings <5 mm Hg apart were obtained for
systolic and diastolic BP.
In this way, everybody complied with the four
following measurement methods: first reading
(Method A), mean of the first two readings; (Method
B), at least four readings and the mean of the last three
readings with <15% coefficient of variation difference;
(Method C), the mean of the first two consecutive
readings with a maximum of 5 mm Hg difference
(Method D).
Data entry and analysis
We used SPSS to set up the database and analyse the
data. All data showed a normal distribution. The mean
BP readings obtained using the different methods were
compared using a general linear model (GLM repeated
measures) and we adjusted the outcome analyses using
the Bonferroni correction. The differences between the
two methods against their means were analysed in a
Bland and Altman plot.
17
Results
The results are presented in Table 2. Of the 287 patients
invited to participate, 223 patients were included in the
study population (78% response). All patients who did
not participate in the study had either limited mobility,
making a visit to the practice impractical, or were
treated for their diabetes by an internist at the hospital.
The average age of the participants was 68.5 years
(range: 36–91 years). In 23% (n = 50) of the patients we
had to use a large occluding cuff to measure the BP
(mean arm circumference of the whole group being
29.8 cm). When applying the rule that BP should be
measured until two readings are obtained that are
<5 mm Hg apart, in 43% (n = 92) two readings sufficed.
On average 3.5 readings were needed to reach this goal.
Table 3 presents a comparison of the different
measuring methods. Nearly all the methods differed
with regard to systolic BP (P<0.001), except C and D.
However, 34% (n = 72) of the patients showed a
difference of >5 mm Hg between methods C and D. For
diastolic BP similar inter-group differences were found
(P<0.001), except between A and B, and between C
and D. Methods C and D resulted in the lowest BP
readings.
Seventy-two percent (n = 161) of patients had a BP
above 150/85 mm Hg, measured according to the
UKPDS method (Method C). Table 4 shows that the
other measuring methods were sensitive (all above
85%) in predicting this target UKPDS value, but only
Method D was specific (86%). For any particular
positive test result, the probability that it is a false
positive (measuring a BP above 150/85 mm Hg while
with the UKPDS method the BP was lower than 150/85
mm Hg) was 34, 29 and 14.5% according to Method A,
Method B, or Method D, respectively.
The Bland and Altman plot analyses between the
UKPDS method and the other methods are illustrated
in Figure 1. These analyses demonstrate large differ-
ences between the different measurement methods.
The regression lines drawn in the plots indicate that the
differences increase as BP increases (except when
comparing the BP between Method D and C).
Discussion
The method used to assess BP determines the level of
the BP found. For example, if the method of the
European Society of Hypertension is used, it results in
systolic and diastolic BP readings that are, respectively,
5.7 and 2.8 mm Hg higher than when the UKPDS
protocol is used. This effect is higher than the
differences that are considered clinically relevant in
large trials (a decrease in systolic BP of 5 mm Hg is
considered significant).
Is this relevant for daily practice? The UKPDS-
method is considered the gold standard in diabetes care.
This implies that there is an overestimation (and
possibly an over-treatment) of the BP in a significant
number of patients (29%) if the method outlined by the
22 Family Practice—an international journalEuropean Society of Hypertension is followed or if
health care professionals are taking only a single
reading (34%). This finding may have implications for
the currently held opinion that BP control in type 2
diabetic patients is generally quite poor.
18–21 If different
measuring protocols are being used, then an artefact
due to inadequate measurement may partially explain
these perceptions.
We found the large differences in BP when we
compared Method A with Method C. A difference
between two methods is more or less irrelevant if the
systolic BP is high (200 mm Hg or more). In contrast, a
difference of 10 mm Hg has direct impact on treatment
decisions if the systolic BP is close to the target value.
We found that 99% of patients with a normal BP
according to the UKPDS-method (<150/85) had a BP
up to 167/92 mm Hg when it was measured only once.
Health care professionals who are measuring once and
who find a BP above 167/92 mm Hg are correctly
qualifying the BP as too high in 99% of the cases
in comparison with the UKPDS method, but the
problem still stands: which target BP is appropriate?
We used, according to the Dutch guidelines, the highest
blood pressure in cases of inter-arm blood pressure
differences >10 mm Hg.
8,10 It would be expected that if
we used a random BP, the differences between methods
would be somewhat less, because of lower average BP
readings.
Another problem affecting daily practice is that the
BP measurement recommendations, such as posture of
subject, arm support, arm position and cuff size,
3 are
rarely followed, and the equipment used is sometimes
inaccurate.
4,5 Besides the differences in measuring
methods between the various guidelines and the
hypertension trials, the description of the method
used inlargehypertensiontrials israther poor (Table1).
Only four of the 11 studies in Table 1 supply a
complete description of the method used, including the
BP measuring device, the number of readings, the time
between measurements, the period the patient waited
before the first measurement and the way in which the
final BP was calculated. In four studies the descriptions
are incomplete, and three studies mentioned hardly any
details. Even when there is an exact description, one
often has to refer to the very first publication of the
study in which the study design is described. These
TABLE 2 Patient characteristics and results of the blood pressure measurement according to the different protocols
Patient characteristics N Results
Sex 223 48% (n = 107) male
Age 223 68.5 years (SD 11.3)
Upper arm circumference 204
a 29.8 cm (SD 3.3)
Number of patients with upper arm circumference >32 cm 219
b 23% (n = 50)
Number of readings required to get 2 consecutive readings
(systolic/diastolic) <5 mm Hg apart
212
c 3.5 measurements (min 2, max 13) (SD 1.9)
Patients in which an x number of readings was sufficient
to get two consecutive readings <5 mm Hg apart
212 2 readings = 43.4% (n = 92)
3 readings = 12.3% (n = 26)
4 readings = 21.7% (n = 46)
5 readings = 9.4% (n = 20)
6 readings = 6.1% (n = 13)
7 readings = 2.8% (n =6 )
>7 readings = 4.3% (n =9 )
Mean blood pressure (systolic/diastolic) Method A 215
d 160.6/88.3 mm Hg (SD 23.4/11.9)
Mean blood pressure (systolic/diastolic) Method B 219
e 159.2/87.9 mm Hg (SD 22.5/11.1)
Mean blood pressure (systolic/diastolic) Method C 218
f 153.7/85.2 mm Hg (SD 21.4/10.0)
Mean blood pressure (systolic/diastolic) Method D 212 152.3/84.9 mm Hg (SD 20.7/9.8)
BP = Blood pressure; Method A: first reading; Method B: mean of first two readings; Method C: at least four readings and the mean of the last three
readings with less than 15% coefficient of variation difference; Method D: mean of first two consecutive readings with a maximum of 5 mm Hg
difference.
a19 cases were not recorded in case-record file (CRF).
b4 cases were not recorded in CRF.
c1 case was not recorded in CRF, and in 10 cases readings were impossible due to pain when readings repeated; large variety in blood pressure
readings due to irregular pulse; or sometimes blood pressure over the maximal capacity [>250 mm Hg systolic].
dIn 8 cases it was not recorded in CRF which reading was first.
e4 patients did not have 2 readings.
f5 patients did not have 4 readings.
Pitfalls in blood pressure measurement 23study design articles are often published in journals that
are not readily available worldwide.
Large hypertension trials are the mainstay for
determining cut-off values in guidelines for the
diagnosis of hypertension and the target values for
treatment. Therefore, measuring protocols used in trials
and in guidelines should be consistent across the board,
allowing easy comparison worldwide, and they should
reflect, and be reflected in, clinical practice. Until
uniform BP measuring methods are used in trials, we
consider a complete and easily available description of
the method used in these trials as an essential minimum
requirement in order to be able to translate the results
of clinical trials into daily practice recommendations.
Only then will the consistency between trials, guidelines
and clinical practice improve. The present international
effort is directed towards stricter cut-off points and
treatment goals. Nevertheless, such goals are easily
undermined when professionals cannot agree upon the
proper assessment and interpretation of the central
point: the measurement method itself.
These results demonstrate that large differences in
BP are found when different measuring methods are
used. These differences are clinically relevant and show
gaps between different methods in trials, guidelines and
daily practice. Our study involved only patients with
TABLE 3 Differences in blood pressure between the different blood pressure measuring methods
ABC D
A N = 215 N = 214 N = 208
MD = 0.3 MD = 3.0 MD = 3.0
95% CI (–0.4 to 1.0) 95% CI (2.0–3.9) 95% CI (1.9–4.2)
P5 = 14.0% (n = 30) P5 = 33.7% (n = 72) P5 = 30.8% (n = 64)
B N = 215 N = 218 N = 212
MD = 1.6 MD = 2.7 MD = 2.8
95% CI (0.6–2.6) 95% CI (2.1–3.7) 95% CI (2.0–3.6)
P5 = 29.3% (n = 63) P5 = 18.8% (n = 41) P5 = 22.1% (n = 47)
C N = 214 N = 218 N = 211
MD = 7.3 MD = 5.7 MD = 0.09
95% CI (5.7–8.9) 95% CI (4.6–6.9) 95% CI (–0.5 to 0.7)
P5 = 66.3% (n = 142) P5 = 56.4% (n = 123) P5 = 11.4% (n = 24)
D N = 208 N = 212 N = 211
MD = 7.9 MD = 6.3 MD = 0.6
95% CI (6.0–9.8) 95% CI (4.7–7.9) 95% CI (–0.7 to 1.9)
P5 = 52.4% (n = 109) P5 = 45.7% (n = 97) P5 = 34.1% (n = 72)
Grey boxes = systolic blood pressure; White boxes = diastolic blood pressure.
Method A: first reading; Method B: mean of first 2 readings; Method C: at least four readings and the mean of the last three readings with >15%
coefficient of variation difference; Method D: mean of first 2 consecutive readings with a maximum of 5 mm Hg difference.
MD: mean difference; P5: percentage patients with >5 mm Hg difference between the two methods; CI = confidence interval.
TABLE 4 Sensitivity, specificity, predictive values and likelihood ratios for a positive and negative test of different measures in predicting the
UKPDS-method blood pressure threshold of >150/85 mm Hg
Sensitivity (%)
a Specificity (%)
a Predictive
value (positive) (%)
a
Predictive value
(negative) (%)
a
Likelihood ratio
(positive)
a
Likelihood ratio
(negative)
a
Method A 95.0 (90.1–97.7) 66.1 (52.9–77.4) 87.9 (81.9–92.2) 83.7 (69.8–92.2) 2.8 (2.0–4.0) 0.08 (0.04–0.15)
Method B 98.8 (95.1–99.8) 71.0 (57.9–81.4) 89.8 (84.2–93.7) 95.7 (84.0–99.3) 3.4 (2.3–5.0) 0.02 (0.01–0.07)
Method D 89.4 (83.4–93.5) 85.5 (73.7–92.7) 94.1 (88.8–97.1) 75.7 (63.7–84.8) 6.2 (3.4–11.3) 0.12 (0.08–0.19)
aWith 95% CI.
Method A: first reading; Method B: mean of first two readings; Method C: at least four readings and the mean of the last three readings with <15%
coefficient of variation difference; Method D: mean of first two consecutive readings with a maximum of 5 mm Hg difference.
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FIGURE 1 Bland and Altman plots of differences between UKPDS method (Method 3) and the other methods. The dotted
horizontal line represents the mean difference between each pair of measurements, the broken line represents the regression line.
**Correlation is significant atthe 0.01level (2-tailed); *Correlationis significant atthe 0.05level (2-tailed).Method A: first reading;
Method B: mean of first 2 readings; Method C: at least four readings and the mean of the last three readings with less than 15%
coefficient of variation difference; Method D: mean of first 2 consecutive readings with a maximum of 5 mm Hg difference
Pitfalls in blood pressure measurement 25diabetes, so it is not certain that the same conclusions
may be applied to the non-diabetic population.
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